Skip to content
foodoseGet my numbers
The foodose BriefScience
ScienceJune 6, 20263 min read

GLP-1s linked to far fewer deaths and heart events in people with autoimmune disease, a group that is mostly women

In 26,000 adults who had both obesity and an autoimmune disease, GLP-1 users had a 44% lower risk of death, plus fewer heart events, ER visits and blood clots. Autoimmune conditions fall mostly on women.

What happened

A study published on 6 June 2026 in the Journal of the American Heart Association, timed to the big diabetes meeting, looked at more than 26,000 adults who had both obesity and an autoimmune disease, and compared those on a GLP-1 with those who were not.

The differences were large. GLP-1 users had a 44% lower risk of dying from any cause, a 31% lower risk of a dangerous lung clot (pulmonary embolism), a 21% lower risk of an emergency-room visit, and a 17% lower risk of blood clots in the veins.

Why this is a women's story

Autoimmune diseases are not evenly shared. Conditions like lupus, rheumatoid arthritis, Hashimoto's thyroid disease and multiple sclerosis fall disproportionately on women, often two to nine times more often than on men. These are also conditions that carry a quietly raised risk of heart disease and clots, partly from the chronic inflammation they cause.

So a finding that GLP-1s may lower death and cardiovascular risk specifically in people with autoimmune disease is, in practice, a finding about a population that is mostly women. That is rare, and worth noticing.

The likely reason: inflammation

This study cannot prove the drug caused the benefit, observational studies never can. But the leading explanation fits a growing pattern. Autoimmune diseases run on inflammation, and inflammation drives heart disease and clots. GLP-1 medications appear to lower inflammation, both by reducing excess fat and through more direct effects. Calm the inflammation, and you may calm the risks that ride on it. (We go deeper on this in how GLP-1s calm inflammation.)

What it means for you

If you live with an autoimmune condition and obesity, this is an encouraging signal worth raising with your doctor, not a reason to change anything on your own. The decision about a GLP-1 still belongs in that conversation, weighed against your full history.

The broader lesson is the one that keeps repeating in 2026: the benefits of these drugs reach well beyond the scale, into the heart, the blood, and the immune system. The number on the scale is the least of it.

What to do with this

This is a reason to stay on the medication, not a change to the plate. The plate is the calculator's job.

Work out your numbers

People also ask
Do GLP-1s help people with autoimmune disease?
A study published on 6 June 2026 in the Journal of the American Heart Association looked at more than 26,000 adults who had both obesity and an autoimmune disease, comparing GLP-1 users with non users. The differences were large: a 44% lower risk of dying from any cause, a 31% lower risk of a dangerous lung clot, a 21% lower risk of an emergency room visit, and a 17% lower risk of blood clots in the veins.
Why is the autoimmune finding particularly relevant to women?
Because autoimmune conditions fall mostly on women. Lupus, rheumatoid arthritis and thyroid disease are all far more common in women than men, so this is one of the first big signals that these drugs may protect a group that is overwhelmingly female and often overlooked in the research.
Read the originalJournal of the American Heart AssociationOpen
Go deeper
GLP-1s and your heart: the protection that starts before the weight comes offRead Beyond weight: how GLP-1s calm inflammation, and why that quietly helps women mostRead The thyroid black-box warning, explained for women on a GLP-1Read

The news changes weekly. What protects your body doesn't.

Work yours out once: your calorie target, your protein floor, and three days of food built to them. Free, and no sign-up.

Get my numbers
More from the Brief
RegulationOctober 8, 2026

Two men charged with smuggling counterfeit Ozempic into the US from China

On 29 September 2026 the FDA and the Justice Department announced charges against two Indian nationals accused of buying counterfeit Ozempic in China and selling it to US distributors from July 2023 to April 2024. Each faces up to 71 years in prison if convicted.

Source: US Food and Drug Administration, US Department of Justice4 min readRead
AccessOctober 8, 2026

Zepbound is back on CVS Caremark's main formularies from 1 October, as more employers drop weight-loss coverage

On 1 October 2026 CVS Caremark restored Zepbound (tirzepatide) as a preferred option on its most common commercial formularies, alongside Wegovy. At the same time, the share of large employers covering GLP-1s for weight fell from 72% in 2025 to 60% in 2026.

Source: CVS Health4 min readRead
TrialsOctober 8, 2026

Adding an amylin drug to tirzepatide: 23.3% weight loss against 14.8% on tirzepatide alone, but more people stopped

In a 48-week phase 2 trial presented at EASD 2026 on 30 September, Lilly's EloraTZP, the amylin drug eloralintide combined with tirzepatide, produced up to 23.3% weight loss in adults with obesity and type 2 diabetes, against 14.8% on tirzepatide 15 mg alone.

Source: Eli Lilly, EASD 20264 min readRead